Table 3.
Clinical diagnosis in the 105 evaluable end-of-life patients who came to autopsy in relation to [18F]flutemetamol PET imaging results (amyloid-positive and amyloid-negative)
| Clinical diagnosisa | Positive (abnormal) (N = 71) | Negative (normal) (N = 34) | Total (N = 105) |
|---|---|---|---|
| AD | 42 (79.2%) | 11 (20.8%) | 53 (50.5%) |
| Other dementing disorder | 19 (79.2%) | 5 (20.8%) | 24 (22.9%) |
| MCI | 0 (0%) | 0 (0%) | 0 (0%) |
| None | 10 (37%%) | 17 (63%) | 27 (25.7%) |
| Memory loss (unspecified) | 0 (0%) | 1 (100%) | 1 (1.0%) |
aAs reported in the case notes